Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Payables (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Payables for 3 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • Quarterly Payables fell 35.71% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2025, down 35.71% year-over-year, with the annual reading at $5.9 million for FY2025, 35.71% down from the prior year.
  • Payables for Q4 2025 was $5.9 million at Inhibrx Biosciences, down from $6.8 million in the prior quarter.
  • The five-year high for Payables was $13.0 million in Q2 2024, with the low at $5.9 million in Q4 2025.
  • Average Payables over 3 years is $9.4 million, with a median of $9.1 million recorded in 2024.
  • The sharpest move saw Payables decreased 15.6% in 2024, then plummeted 45.25% in 2025.
  • Over 3 years, Payables stood at $11.0 million in 2023, then fell by 15.6% to $9.2 million in 2024, then plummeted by 35.71% to $5.9 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $5.9 million, $6.8 million, and $8.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.